李敏勇，男，1976年9月出生，博士，药学院药物化学专业教授、博士生导师。李敏勇，男，1976年9月出生，博士，山东大学药学院药物化学专业教授、博士生导师。1995.9 – 1999.7 中国药科大学药物制剂专业学习，获工学士学位；2000.9 – 2005.6 中国药科大学药物化学专业学习，获理学博士学位；2003.7 － 2003.9 北京大学天然药物与仿生药物国家重点实验室进行客座研究；2005.9 – 2007.10 美国佐治亚州立大学(Georgia State University)化学系进行博士后研究工作；2007.10 – 2009.4美国佐治亚州立大学(Georgia State University)化学系助理教授；2009.4- 至今 山东大学药学院药物化学研究所关键岗教授、博士生导师。李敏勇为American Chemical Society、Cheminformatics and QSAR Society、Sigma Xi, the Scientific Research Society、中国化学会会员和中国药学会高级会员，曾担任Chemical Communication、Physical Chemistry Chemical Physics、Molecular BioSystems、Organic & Biomolecular Chemistry、Chemical Biology & Drug Design、Journal of Computational Chemistry、Journal of Molecular Modeling、Journal of Computer-Aided Molecular Design、FEBS Letters、Bioorganic Medicinal Chemistry Letters、Bioorganic Medicinal Chemistry、Journal of Global Infectious Diseases、Journal of Biological Research、Molecules、Journal of Medicinal Plants Research、Letters in Drug Design & Discovery和Drug Design, Development and Therapy等国际学术杂志审稿人，同时任Current Topics in Medicinal Chemistry杂志的特邀编委。李敏勇教授主要研究方向为药物化学与化学生物学研究，综合应用合理药物设计、计算机辅助药物分子设计和分子生物学等手段进行药物化学和化学生物学研究工作。1. 华实海洋药物奖励基金管理委员会，首届华实海洋药物青年科技奖二等奖，20092. ELSEVIER中国科技部，SCOPUS青年科学之星，2009承担主要科研项目情况1. 芳基磺酰类新型抗菌活性化合物的研究，山东省中青年科学家科研奖励基金(BS2009SW011)，5万，主持，2009.12-2012.122. SecA ATPase 抑制剂的抗菌活性研究，高等学校博士学科点专项科研基金(20090131120080)，3.6万，主持，2010.1-2012.123. 药效团与骨架跃迁策略在天然先导优化中的应用研究，霍英东教育基金会高等院校青年教师基金 (122036)，2万美元，主持，2010.5-2013.44. AI-2型群体感应抑制剂的抗菌活性研究，国家自然科学基金(81001362)，23万，主持，2011.1-2013.125. α1-肾上腺素能受体的荧光探针研究，山东大学自主创新基金自然科学类专项杰出青年基金(2010JQ005)，30万，主持，2010.6-2012.126. 分子探针在药物研究中的应用，山东省自然科学基金杰出青年基金(JQ201019)，50万，主持，2010.10-2013.10目前已发表60余篇SCI论文，其中第一或通讯作者有29篇，被SCI引用次数有380余次，被引用H指数(H index)为13，申请中国、美国和世界专利8项，目前作为课题负责人主持国家自然科学基金、山东省自然科学杰出青年基金、霍英东教育基金会高等院校青年教师基金、教育部博士点专项资金、山东省中青年优秀科学家科技奖励基金、山东大学自主创新基金自然科学类专项杰出青年基金等多项科研项目，总经费130余万元。由于在化学与生命科学领域的突出贡献，李敏勇教授获得了2009年“华实海洋药物青年科技奖”、“SCOPUS青年科学之星”等多项科技奖励，并多次受邀在国内和国际学术会议上做学术报告。1. 基于生物靶标的合理药物设计、合成及生物活性研究主要围绕与疾病相关如AI-2型细菌群体效应受体LuxP、细菌SecA ATPase、α1-肾上腺素能受体、钾离子通道等生物靶点，以有机化学、药物化学、计算化学等方法为研究手段，进行基于靶点结构的合理药物分子设计、合成与生物活性研究。2. 化学生物学研究通过合理设计、合成、生物筛选、分离、富集等手段，获得能与氨基酸、蛋白、有机小分子、无机离子等靶物质特异性结合的配体和探针。1. Li, M. Y.; Du, L. P.; Wu, B.; Xia, L. Self-organizing molecular field analysis on α1a-adrenoceptor dihydropyridine antagonists. Bioorg. Med. Chem. 2003, 11, 3945-3951.2. Li, M. Y.; Tsai, K. C.; Xia, L. Pharmacophore identification of α1A-adrenoceptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 657-664.3. Li, M. Y.; Fang, H.; Xia, L. Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as α1-adrenoceptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 3216-3219.4. Li, M. Y.; Lu, J. F.; Xia, L. Receptor-based molecular modeling study on antagonist-bound human α1A, α1B and α1D-adrenoceptors. Acta Chim. Sinica 2005, 63, 1875-1883.5. Li, M. Y.; Wang, B. H. Computational studies of H5N1 hemagglutinin binding with SA-α-2, 3-Gal and SA-α-2, 6-Gal. Biochem. Biophys. Res. Commun. 2006, 347, 662-668. (Top 10 Hottest Articles on Biochemical and Biophysical Research Communications on July – September 2006)6. Li, M. Y.; Xia, L. Rational design, synthesis, biological evaluation, and structure-activity relationship studies of novel 1-indanone α1-adrenoceptor antagonists. Chem. Biol. Drug Des. 2007, 70, 461-464.7. Li, M. Y.; Wang, B. H. Homology modeling and examination of the effect of the D92E mutation on the H5N1 nonstructural protein NS1 effector domain. J. Mol. Model. 2007, 13, 1237-1244.8. Yang, Q.; Wang, Y. J.; Du, L. P.; Li, M. Y.*; You, Q. D. Strategies for atrial fibrillation therapy: focusing on IKur potassium channel. Expert Opin. Ther. Patents 2007, 17, 1443-1456.9. Li, M. Y.; Huang, Y. J.; Tai, P. C.; Wang, B. H. Discovery of the first SecA inhibitors using structure-based virtual screening. Biochem. Biophys. Res. Commun. 2008, 368, 839-845.10. Ni, N. T.; Chou, H. T.; Wang, J. F.; Li, M. Y.; Lu, C. D.; Tai, P. C.; Wang, B. H. Identification of boronic acids as antagonists of bacterial quorum sensing in Vibrio harveyi. Biochem. Biophys. Res. Commun. 2008, 369, 590-594.11. Li, M. Y.*; Ni, N. T.; Wang, B. H.; Zhang, Y. Q. Modeling the excitation wavelengths (λex) of boronic acids. J. Mol. Model. 2008, 14, 441-449.12. Yang, Q.; Du, L. P.; Wang, X. J.; Li, M. Y.*; You, Q. D. Modeling the binding modes of Kv1.5 potassium channel and blockers. J. Mol. Graph. Model. 2008, 27, 178-187.13. Li, M. Y.; Ni, N. T.; Chou, H. T.; Lu, C. D.; Tai, P. C.; Wang, B. H. Structure-based discovery and experimental verification of novel Al-2 quorum sensing inhibitors against Vibrio harveyi. ChemMedChem 2008, 3, 1242-1249.14. Tsai, K. C.; Wang, S. H.; Hsiao, N. W.; Li, M. Y.*; Wang, B. H. The effect of different electrostatic potentials on docking accuracy: A case study using DOCK5.4. Bioorg. Med. Chem. Lett. 2008, 18, 3509-3512.15. Li, M. Y.*; Fang, H.; Du, L. P.; Xia, L.; Wang, B. H. Computational studies of the binding site of α1A-adrenoceptor antagonists. J. Mol. Model. 2008, 14, 957-966.16. Li, M. Y.; Lin, N.; Huang, Z.; Du, L. P.; Altier, C.; Fang, H.; Wang, B. H. Selecting aptamers for a glycoprotein through the incorporation of the boronic acid moiety. J. Am. Chem. Soc. 2008, 130, 12636-12638. (Highlighted by Faculty of 1000 Biology)17. Yang, Q.; Du, L. P.; Wang, X. J.; Li, M. Y.*; You, Q. D. Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR Comb. Sci. 2009, 28, 59-71.18. Li, M. Y.* The medicinal chemistry of ion channels and their relevance in drug discovery. Curr. Top. Med. Chem. 2009, 9, 321.19. Du, L. P.; Li, M. Y.*; You, Q. D. The interactions between hERG potassium channel and blockers. Curr. Top. Med. Chem. 2009, 9, 330-338.20. Yang, Q.; Wang, X. J.; Du, L. P.; Li, M. Y.*; You, Q. D. Drug discoveries towards Kv1.5 potassium channel. Curr. Top. Med. Chem. 2009, 9, 339-347.21. Jin, S., Choudhary, G., Cheng, Y.F., Dai, C.F., Li, M.Y.* and Wang, B.H., Fluoride Protects Boronic Acids in Copper (I)-mediated Click Reaction, Chem. Commun., 2009, 5251-5253.22. Cheng, Y.F., Li, M.Y.*, Wang, S.R., Peng, H.J., Reid, S., Ni, N.T., Fang, H., Xu, W.F. and Wang, B.H., Carbohydrate Biomarkers for Future Disease Detection and Treatment, Sci. China Chem. 2010, 53, 3-20.23. Du, L.P., Ni, N.T., Li, M.Y.* and Wang, B.H., A Fluorescent Hydrogen Peroxide Probe Based on a ‘Clickable’ Coumarin Fluorophore, Tetrahedron Lett. 2010, 51, 1152-1154.24. Tsai, K.C., Wang, S.H., Hsiao, N.W., Li, M.Y.*, and Wang, B.H., A Comparsion of Different Electrostatic Potentials on Prediction Accuracy using CoMFA and CoMSIA Studies, Eur. J. Med. Chem. 2010, 45, 1544-1551.25. Wang, X.J., Yang, Q., Yin, D.L., Li, M.Y.* and You, Q.D., in silico Binding Characteristics between Human Histamine H1 Receptor and Antagonists, J. Mol. Model., 2010, 16, 1529-1537.26. Du, L.P. and Li, M.Y. *, Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists, Curr. Comput. Aid. Drug Des. 2010, 6, 165-178.27. Sun, W., Du, L.P. and Li, M.Y.*, Aptamer-based Carbohydrate Recognition, Curr. Pharm. Des., 2010, 16, 2269-2278.28. King-Keller, S., Li, M.Y., Smith, A., Zheng, S., Kaur, G., Yang, X., Wang, B.H. and Docampo, R. Chemical Validation of Phosphodiesterase C as a Chemotherapeutic Target in Trypanosoma cruzi, the Etiological Agent of Chagas' Disease, Antimicrob. Agents Chemother., 2010, 54, 3738-3745 (co-first author)29. Yang, Q., Fedida, D., Xu, H., Wang, B., Du, L., Wang, X., Li, M.Y.* and You, Q.D. Structure-Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of Kv1.5 Channel Blockers, ChemMedChem, 2010, 5, 1353-1358.
山东大学 